KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Construction in Progress: 2016-2024

Historic Construction in Progress for BeOne Medicines (ONC) over the last 8 years, with Dec 2024 value amounting to $654.0 million.

  • BeOne Medicines' Construction in Progress fell 79.36% to $129.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.1 million, marking a year-over-year decrease of 79.36%. This contributed to the annual value of $654.0 million for FY2024, which is 11.69% down from last year.
  • BeOne Medicines' Construction in Progress amounted to $654.0 million in FY2024, which was down 11.69% from $740.6 million recorded in FY2023.
  • BeOne Medicines' Construction in Progress' 5-year high stood at $740.6 million during FY2023, with a 5-year trough of $85.8 million in FY2020.
  • Over the past 3 years, BeOne Medicines' median Construction in Progress value was $654.0 million (recorded in 2024), while the average stood at $562.8 million.
  • In the last 5 years, BeOne Medicines' Construction in Progress surged by 309.35% in 2020 and then decreased by 11.69% in 2024.
  • BeOne Medicines' Construction in Progress (Yearly) stood at $85.8 million in 2020, then soared by 117.82% to $186.8 million in 2021, then skyrocketed by 57.15% to $293.6 million in 2022, then spiked by 152.23% to $740.6 million in 2023, then decreased by 11.69% to $654.0 million in 2024.